Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q2 revenue of $243.6 million, up 55% year-over-year, driven by growth in ARCALYST prescriptions for recurrent pericarditis. Management raised full-year 2026 ARCALYST guidance to $980 million-$995 million, up from the previous $930 million-$945 million range.
Key figures
- Eps
- 0.3
- Revenue
- 243600000
- Guidance
- 2026 ARCALYST net product revenue $980M - $995M, raised from $930M - $945M
- Revenue Yoy
- 55%
- Net income
- 25400000
- Cash position
- 525900000
- Phase2 time to pain response days
- 4
- Phase2 time to crp normalization days
- 8
- Phase2 time to treatment response days
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.